Rituximab in Combination with CHOP, an Effective and Well-tolerated Salvage Regimen for Diffuse Large B-Cell Lymphoma

REFERENCES

1. ↵
   1. Jermann M,
   2. Jost LM,
   3. Taverna CH, et al.

   Rituximab–EP-OCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol 2004;15:511–516.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   1. Kewalramani T,
   2. Zelenetz AD,
   3. Nimer SD, et al.

   Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103:3684-3688.

   OpenUrlAbstract/FREE Full Text
3. ↵
   1. Cragg MS,
   2. Glennie MJ

   . Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004;03:738-2743.

   OpenUrl
4. ↵
   1. Kim DH,
   2. Jung HD,
   3. Kim JG, et al.

   FcγRIIIa gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 2006;108:2720-2725.

   OpenUrlAbstract/FREE Full Text
5. ↵
   1. Mathas S,
   2. Rickers A,
   3. Bommert K, et al.

   Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res 2000;60:7170-7176.

   OpenUrlAbstract/FREE Full Text
6. ↵
   1. Mounier N,
   2. Briere J,
   3. Gisselbrecht C, et al.

   Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood,2003;101:4279-4284.

   OpenUrlAbstract/FREE Full Text
7. ↵
   1. Marcus R,
   2. Imrie K,
   3. Belch A, et al.

   CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-1423.

   OpenUrlAbstract/FREE Full Text
8. ↵
   1. Coiffier B,
   2. Haioun C,
   3. Ketterer N, et al.

   Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998;92: 1927-1932.

   OpenUrlAbstract/FREE Full Text
9. ↵
   1. Kunzmann V,
   2. Ruediger T,
   3. Hallek M, et al.

   Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment. Blood 2001;98:1991-1992.

   OpenUrlFREE Full Text
10. ↵
    1. Schmits R,
    2. Schmitz N,
    3. Pfreundschuh M, et al.

    The best treatment for diffuse large B-cell lymphoma: a German perspective. Oncology 2005;19:16-25.

    OpenUrl